Gilead Sciences is a biopharmaceutical company focused on antiviral drugs, oncology, and cell therapy. As a corporate venture investor, it has made over 40 investments in life sciences companies across stages.
45% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (73% of deals). Average disclosed round size is $80.5M (across 10 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| KKyverna Therapeutics | Series B | $60M | Aug 2023 |
 Curebase | Series B | $40M | May 2023 |
| Curebase | Series B | $40M | May 2022 |
 Barinthus Biotherapeutics | Series B | $168M | Mar 2021 |
 Vaccitech | Series B | $168M | Mar 2021 |
| LLyndra Therapeutics Inc. | Series C | $55M | Jan 2019 |
 Pionyr Immunotherapeutics | Series B | $62M | Dec 2017 |
| EEpiTherapeutics | Seed | — | Dec 2010 |
 Precision BioSciences | Series B | $110M | — |
 Tentarix Biotherapeutics | Series B | $35M | — |
 HiFiBiO Therapeutics | Series C | $67M | — |
Top Co-Investors
Korea Investment Partners2 shared
Osage University Partners2 shared
Future Planet Capital2 shared
LYFE Capital2 shared
Industry Ventures1 shared
GGV Capital1 shared
Acrew Capital1 shared
Xfund1 shared
Positive Sum1 shared
Bold Capital Partners1 shared
Gaingels1 shared
World Innovation Lab1 shared
SV Angel1 shared
Gates Foundation1 shared
Polaris Partners1 shared
Hopu Investments1 shared
The Invus Group, LLC1 shared
venBio1 shared
Cowen Healthcare Investments1 shared
Adage Capital Management1 shared
Last updated: 7 September 2026